Axsome Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Axsome Therapeutics (NASDAQ: AXSM) has started the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. The trial will evaluate the efficacy and safety of AXS-05 compared to bupropion and placebo. AXS-05 is already approved for major depressive disorder and agitation associated with Alzheimer's disease but not for smoking cessation.
Axsome Therapeutics (AXSM) reported Q4 revenue of $196M, up 65% YoY, beating estimates. Net loss was $0.56 per share, better than expected. Analyst Joseph Thome raised the price target to $215, citing strong product growth and upcoming regulatory milestones. The company expects FDA decisions on key drugs in 2026.
UBS raised its price target on Axsome Therapeutics to $280 from $259 and kept a Buy rating, according to the brokerage. The article also notes Mizuho adjusted its target to $316 from $306 and maintained an Outperform rating. These changes may affect investor expectations for the stock.
Over the past 7 days, alphai's AI scored 4 news stories mentioning AXSM (Axsome Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent AXSM coverage spans financial news, earnings and technology.
In the last 30 days, AXSM insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($10.5M). The most active reporter was TABUTEAU HERRIOT, Chief Executive Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The start of a pivotal Phase 3 trial could unlock a new indication for AXS-05, expanding revenue potential.
Positive earnings beat and upgraded price target likely support short-term upside.
The article is a sell-side target change for AXSM, likely supportive near-term sentiment but not a fundamental catalyst by itself.
Near-term trading focus is AUVELITY/SYMBRAVO commercial momentum and the FDA acceptance milestone for AXS-12, which can re-rate pipeline risk.
The article frames a near-term investment tradeoff: faster revenue growth alongside worsening losses and cash burn, tied to expanding CNS commercialization and R&D.
alphai scores every news story that mentions AXSM with an AI model for sentiment and relevance, and aggregates insider trades from Axsome Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Axsome Therapeutics (NASDAQ: AXSM) has started the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. The trial will evaluate the efficacy and safety of AXS-05 compared to bupropion and placebo. AXS-05 is already approved for major depressive disorder and agitation associated with Alzheimer's disease but not for smoking cessation.
2 min readAxsome Therapeutics (AXSM) reported Q4 revenue of $196M, up 65% YoY, beating estimates. Net loss was $0.56 per share, better than expected. Analyst Joseph Thome raised the price target to $215, citing strong product growth and upcoming regulatory milestones. The company expects FDA decisions on key drugs in 2026.
2 min readUBS raised its price target on Axsome Therapeutics to $280 from $259 and kept a Buy rating, according to the brokerage. The article also notes Mizuho adjusted its target to $316 from $306 and maintained an Outperform rating. These changes may affect investor expectations for the stock.
2 min readAxsome Therapeutics (AXSM) reported Q2 updates on AUVELITY, SYMBRAVO, and SUNOSI, including gross-to-net discounts and prescription growth. AUVELITY was launched for Alzheimer’s agitation, with total prescriptions about 266,000. SYMBRAVO prescriptions rose to about 23,500. FDA accepted AXS-12 NDA with a May 1, 2027 target date. Costs and expenses were also detailed.
6 min readAxsome Therapeutics reported Q2 2026 results: revenue rose to $218.38M from $150.04M a year earlier, while net loss widened to $51.31M and basic loss per share from continuing operations increased to $0.99. The article notes FDA acceptance of the AXS 12 NDA for narcolepsy and discusses how faster revenue growth with wider losses affects the investment case.
7 min readThe article reports multiple US corporate updates. Barrick Mining said Q2 profit rose 50% to $1.22B, with revenue up 44% to $5.29B, and agreed with Newmont on a $1.95B cash top-up to expand Nevada Gold Mines. Nvidia is working on a $500B AI financing venture; Intel announced a $15B stock offering. It also covers results for Axsome (revenue +46%), Monday.com, RadNet, NESR, and Camtek.
7 min readAxsome Therapeutics, Inc. (AXSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY ® 2Q 2026 net product sales of $180.3 million, representing 51% year-ov
6 min readTABUTEAU HERRIOT (Chief Executive Officer) sold 49,664 shares of Axsome Therapeutics, Inc. (AXSM) at an average of $212.19 ($212.01–$213.95, $10.54M total) across 2 trades over 2026-08-05 to 2026-08-06 under a Rule 10b5-1 trading plan.
2 min readThe article highlights Axsome Therapeutics (AXSM) and Moderna (MRNA) as stocks expected to perform despite macro and geopolitical risks. For AXSM, Q1 revenue rose 57% to $191.2M, but operating loss widened to $63.4M. It cites FDA acceptance for AXS-12, with potential approval by May 2027. For MRNA, it notes FDA panel support for mFLUSIVA and Q2 revenue of $145M, up 2% YoY.
6 min readAnalysts initiated coverage on several stocks. BMO Capital began coverage of Insmed (NASDAQ:INSM) with an Outperform rating and $192 target, and Axsome Therapeutics (NASDAQ:AXSM) with an Outperform rating and $310 target. Compass Point started American Healthcare REIT (NYSE:AHR) at Buy with $70 target. BMO initiated Trevi Therapeutics (NASDAQ:TRVI) at Outperform with $36 target, and Rodman & Renshaw started Eledon Pharmaceuticals (NASDAQ:ELDN) at Buy with $12 target.
2 min read
